Xencor Inc. (NASDAQ:XNCR) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $22.46 and last traded at $22.13, with a volume of 134,926 shares. The stock had previously closed at $21.50.

XNCR has been the subject of several research analyst reports. TheStreet upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Monday, April 25th. Canaccord Genuity restated a “buy” rating on shares of Xencor in a research note on Tuesday, May 3rd. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Xencor in a research note on Monday, May 2nd. Wedbush restated an “outperform” rating and issued a $27.00 price objective on shares of Xencor in a research note on Tuesday, June 28th. Finally, Leerink Swann restated an “outperform” rating and issued a $18.00 price objective on shares of Xencor in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $22.33.

The company has a market capitalization of $915.55 million and a P/E ratio of 23.85. The firm’s 50-day moving average is $17.80 and its 200 day moving average is $13.90.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $1.31. The business had revenue of $66 million for the quarter, compared to analyst estimates of $7.43 million. On average, equities analysts predict that Xencor Inc. will post $0.72 EPS for the current year.

In related news, VP John R. Desjarlais sold 5,905 shares of the company’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $20.00, for a total value of $118,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bassil I. Dahiyat sold 45,886 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $13.00, for a total value of $596,518.00. Following the completion of the sale, the chief executive officer now directly owns 358,186 shares of the company’s stock, valued at $4,656,418. The disclosure for this sale can be found here.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.